Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
54.23 USD +1.84% Intraday chart for Bristol-Myers Squibb Company +5.12% +5.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bristol-Myers Solicits Proxies from the Shareholders CI
Bristol-Myers Solicits Proxies from the Shareholders CI
Bristol Myers Squibb Drug Misses Endpoint in Crohn's Disease Trial DJ
Bristol-Myers Squibb's Phase 3 Trial of Crohn's Disease Treatment Fails to Meet Primary Endpoint MT
Bristol Myers' bowel disease drug fails to meet main goal in late-stage study RE
Bristol Myers Squibb Announces Pivotal KRYSTALl-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer CI
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia in Patients with Moderate to Severe Active Crohn's Disease CI
Bristol Myers: initiatives to advance health equity CF
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 CI
Q32 Bio Inc. announced that it has received $42 million in funding from a group of investors CI
Bristol Myers: Abecma approved by the European Union CF
Bristol-Myers Squibb's Multiple Myeloma Treatment Gets European Commission Approval MT
Bristol Myers Squibb Gets EU OK for Cancer Treatment DJ
Bristol Myers Squibb?s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma CI
Bristol-Myers Squibb's Phase 3 Hepatocellular Carcinoma Study Meets Overall Survival Goal MT
Bristol Myers: conclusive results for Opdivo + Yervoy CF
Bristol Myers Opdivo/Yervoy Combo Hits Main Goal in Liver Cancer DJ
Bristol Myers liver cancer treatment meets main goal of late-stage study RE
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo Plus Yervoy Meets Primary Endpoint of Overall Survival CI
Capstan Therapeutics, Inc. announced that it has received $175 million in funding from a group of investors CI
PureTech shares jump on USD100 million tender offer proposal AN
Bristol-Myers Squibb Company Announces Gerald Storch Not to Stand for Re-Election to the Board CI
Bristol-Myers Squibb Receives a Shareholder Proposal from John Chevedden CI
Bristol-Myers Squibb Receives a Shareholder Proposal from Kenneth Steiner CI
Bristol-Myers Squibb Receives a Shareholder Proposal New York City Carpenters Pension Fund CI
Chart Bristol-Myers Squibb Company
More charts
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
54.23 USD
Average target price
56.41 USD
Spread / Average Target
+4.02%
Consensus
  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
  4. News Bristol-Myers Squibb Company
  5. Insider Trends: 90-Day Insider Buying Trend Reduced with Disposition of Bristol-Myers Squibb Shares